Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer diseaseReport as inadecuate

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease - Download this document for free, or read online. Document in PDF available to download.

Croatian medical journal, Vol.55 No.4 August 2014. -

Alzheimer disease AD is a complex neurodegenerative

disorder, whose prevalence will dramatically rise by 2050.

Despite numerous clinical trials investigating this disease,

there is still no effective treatment. Many trials showed

negative or inconclusive results, possibly because they recruited

only patients with severe disease, who had not undergone

disease-modifying therapies in preclinical stages

of AD before severe degeneration occurred. Detection of

AD in asymptomatic at risk individuals and a few presymptomatic

individuals who carry an autosomal dominant monogenic

AD mutation remains impractical in many of clinical

situations and is possible only with reliable biomarkers.

In addition to early diagnosis of AD, biomarkers should

serve for monitoring disease progression and response to

therapy. To date, the most promising biomarkers are cerebrospinal

fluid CSF and neuroimaging biomarkers. Core

CSF biomarkers amyloid β1-42, total tau, and phosphorylated

tau showed a high diagnostic accuracy but were still

unreliable for preclinical detection of AD. Hence, there is

an urgent need for detection and validation of novel CSF

biomarkers that would enable early diagnosis of AD in

asymptomatic individuals. This article reviews recent research

advances on biomarkers for AD, focusing mainly on

the CSF biomarkers. In addition to core CSF biomarkers, the

potential usefulness of novel CSF biomarkers is discussed.

Author: Mirjana Babić - orcid.org-0000-0003-4223-4190 ; Department of Neuroscience Croatian Institute for Brain Research, University of

Source: http://hrcak.srce.hr/


Related documents